A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

Schizophrenia is a serious and long-lasting mental health condition that affects around 1 in 100 people. It can cause a range of symptoms, including seeing or hearing things that aren't there (hallucinations) and having strong false beliefs (delusions). While current medicines, called antipsychotics, are good at helping with these symptoms, they often don't do much for other common problems, like difficulties with memory, concentration, and planning – often called 'cognitive' symptoms. These cognitive challenges can make it hard for people to go to work, study, or manage daily life.

This study is looking at a new medicine called Xanomeline/Trospium (XT), which works in a different way to existing treatments. XT targets a specific chemical system in the brain to help with symptoms, while trying to limit unwanted side effects in other parts of the body. XT has already been approved in 2024 for treating other symptoms of schizophrenia because it has been shown to be effective and generally safe in earlier studies. However, researchers now want to take a much closer look at its potential benefits for thinking and memory skills.

Most studies on schizophrenia medicines haven't focused enough on long-term changes in thinking and memory. This new study is important because it will be the first to thoroughly examine these cognitive effects over a whole year of treatment with XT. It will also explore how any changes in thinking skills relate to other important aspects of life, such as how well symptoms are controlled, how easily someone can manage daily tasks, and their overall quality of life. The results could help doctors and patients choose treatments that not only control common symptoms but also significantly improve thinking and memory, ultimately supporting a better recovery and daily life.